Standout Papers

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Lar... 2002 2026 2010 2018 3.9k
  1. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma (2002)
    Bertrand Coiffier, Éric Lepage et al. New England Journal of Medicine
  2. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte (2010)
    Bertrand Coiffier, Catherine Thiéblemont et al. Blood
  3. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study (2017)
    Michael Crump, Sattva S. Neelapu et al. Blood

Immediate Impact

4 by Nobel laureates 11 from Science/Nature 79 standout
Sub-graph 1 of 19

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
CAR T Cells and T-Cell Therapies for Cancer
2024 Standout

Works of Éric Van Den Neste being referenced

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
2018
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout

Author Peers

Author Last Decade Papers Cites
Éric Van Den Neste 5335 1918 4120 45 7.0k
Félix Reyes 5367 2067 3641 55 7.3k
P Lederlin 5002 1986 3209 76 6.3k
Richard Klasa 5680 2344 3964 104 7.3k
Mukesh Chhanabhai 4681 1403 2898 48 5.5k
ML Cleary 4955 2084 3111 49 7.5k
Réda Bouabdallah 5579 2301 4225 124 8.0k
Hans Hagberg 3961 1782 3064 136 6.2k
Michele Ghielmini 6279 2971 4442 134 8.6k
F Reyes 3388 1513 2278 62 4.8k
Jan Walewski 4453 1855 4145 207 6.8k

All Works

Loading papers...

Rankless by CCL
2026